The Predictive Value Of FAS MRNA For Prognosis And Anti-cancer Drug Sensitivity In Breast Cancer

FAS/CD95 receptor belongs to the well-known tumor necrosis factor(TNF)receptor family and was firstly identified as being involved in apoptosis associated pathway of different types of tumor cells.Further studies revealed that FAS had a role in pathways that contributed to tumor growth and invasion.In our earlier study,we had described that FAS was of distinct prognostic value in several malignancies and it was significantly correlated to better prognosis in breast cancer.Here we further investigated the prognostic value of FAS mRNA in breast cancer with different phenotypes and clinicopathological parameters.We also studied the correlation between FAS mRNA expression level and sensitivities of anti-cancer drugs.Methods:Based on the datasets from online KM-Plotter,we investigated the correlation between FAS mRNA expression and the prognosis of breast cancer patients with different subtypes and clinic-pathological parameters.Relying on the data from Cell Miner Tool of 60 cell lines,we analyzed the association between FAS mRNA expression and efficacies of several systematic therapeutic drugs for breast cancer.Results:The FAS mRNA expression level was significantly lower in breast cancer compared to normal breast tissue.The higher FAS mRNA expression level was associated with better prognosis in every phenotype of breast cancer,but not in grade I and nodal status negative patients.The FAS mRNA expression was negatively correlated to the efficacies of typical chemotherapeutic agents for breast cancer-Paclitaxel(R^2=0.127,p=0.005)and Docetaxel(R^2=0.119,p=0.015).But the tumor with higher expression level of FAS mRNA is more sensitive to Olaparib(R^2=0.091,p=0.025)and Everolimus(R^2=0.174,p=0.001).Conclusion:We elucidate that FAS serves as a reliable prognostic biomarker in breast cancer and can be used to predict the efficacy of certain chemotherapy agents and targeted drugs in breast cancer.